Cancer, neurology, immune therapies drive continued robust pace of biopharma financings

2017 was recorded as the second highest financings year for the biopharmaceutical industry. High enthusiasm was demonstrated among investors who funneled about two-thirds of the money through public offerings. BioPharma Financings Reports, 15 separate analyses compiled by BioWorld and Clarivate Analytics focused on key therapeutic markets, found that in addition to cancer companies, firms working […]